Reduction of Healthcare Resource Utilisation and Costs Following the Use of Risperidone for Patients with Schizophrenia Previously Treated with Standard Antipsychotic Therapy: A Retrospective Analysis Using the Saskatchewan Health Linkable Databases

Clinical Drug Investigation

Volumn 11, Issue 5, 1996, Pages 289-299

  Albright, Penny S ^a   Livingstone, Scott ^b   Keegan, David L ^c   Ingham, Michael ^a   Shrikhande, Satish ^c   Le Lorier, Jacques ^d  

^a Janssen Ortho Inc   (Canada)

^b Saskatchewan Health   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; CANADA; COHORT ANALYSIS; COST CONTROL; DATA BASE; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA;

EID: 0029955270     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199611050-00005     Document Type: Article

References (24)

1. Chouinard G, Arnott W. Clinical review of risperidone. Can J Psychiatry 1993; 38 Suppl. 3: S89-95
2. Keegan D. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug. Can J Psych 1994; 39 9 Suppl.: S46-52
3. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebocontrolled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-35
4. Borison RL, Pathiraja AP, Diamond BL, et al. Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28: 213-8
5. Remington G. Clinical consideration in the use of risperidone. Can J Psychiatry 1993; 38 Suppl. 3: S96-100
6. Andreasen NC. Assessment issues and the cost of schizophrenia. Schizophr Bull 1991; 17: 475-81
7. Wasylenki DA. The cost of schizophrenia. Can J Psychiatry 1994; 39 Suppl. 2: S65-9
8. Wyatt R. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17 (2): 325-51
9. Kane J, Marder S. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19 (2): 113-28
10. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994; 165 Suppl. 25; 18-21
11. Addington DE, Jones B, Bloom D, et al. Reduction in hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917-26
12. Strand LM, Downey W. Health databases in Saskatchewan. Strom BL, editor. Pharmacoepidemiology. 2nd ed. West Sussex, UK: John Wiley and Sons Ltd, 1994
13. Saskatchewan Health Prescription Drug Services Formulary. 41st ed. Regina Saskatchewan: 1995
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987
15. Government of Saskatchewan. Saskatchewan Health Annual Statistical Report 1992-93. Regina: Saskatchewan
16. Government of Saskatchewan. Saskatchewan Health Annual Statistical Report 1993-94. Regina: Saskatchewan
17. Reid WH. The treatment of psychosis: resetting the drug cost 'thermostat'. J Clin Psychiatry 1994; 55 9 Suppl. B: 166-8
18. Chiles JA, Davidson P, McBride D. Effects of clozapine on the use of seclusion and restraint. Hosp Community Psychiatry 1994; 45: 269-71
19. Arnold SE, Gur RE, Shapiro RM, et al. Prospective clinicopathologic studies of schizophrenia: accrual and assessment of patients. Am J Psychiatry 1995; 152 (5): 731-7
20. Hatfield AB, Spaniol L, Zipple AM. Expressed emotion: a family perspective. Schizophr Bull 1987; 13 (2): 221-6
21. Bellack AS, Mueser KJ. Psychosocial treatment for schizophrenia. Schizophr Bull 1990; 19 (2): 142-62
22. Hogarty GE. Prevention of relapse in chronic schizophrenia patients. J Clin Psychiatry 1993; 3 Suppl.: 18-23
23. Harding CM, Brookes G, Ashikaga P, et al. The Vermont longitudinal study of persons with severe mental illness. I. Methodology, study sample and overall status 32 years later. Am J Psychiatry 1987; 144: 718-26
24. Harding CM, Brookes G, Ashikaga P, et al. The Vermont longitudunal study of persons with severe mental illness. II. Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry 1987; 144: 727-35